The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
-
Page/Page column 17
(2008/06/13)
Indazole-carboxamide compounds
The invention provides novel indazole-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
-
Page/Page column 22
(2008/06/13)
5-HT4 receptor agonist compounds
The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
-
Page/Page column 19
(2008/06/13)
Quinolinone compounds as 5-HT4 receptor agonists
The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
-
Page/Page column 22
(2008/06/13)
Antibacterial compounds
Bacterial protein synthesis-inhibiting compounds having formula (I) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates in the processes, compositions containing the compounds, and methods of using the compounds are disclosed.
-
Page/Page column 17
(2010/02/12)
Monocyclic Analogues of the μ-Opioid Agonist 3,8-Diazabicyclooctanes: Synthesis, Modeling, and Activity
Several monocyclic derivatives structurally related to the μ-opioid agonist 3-cinnamyl-8-propionyl-3,8-diazabicyclooctane have been synthesized and tested in binding studies using the μ-selective 3H-DAMGO as ligand.Modeling studies have been performed on the same compounds in order to explain the observed lack of affinity towards μ-opioid receptors.
Barlocco, Daniela,Villa, Stefania,Fratta, Walter,Fadda, Paola,Colombo, Diego,Toma, Lucio
p. 11547 - 11556
(2007/10/02)
More Articles about upstream products of 172477-98-4